Compare · OXY vs PRTG
OXY vs PRTG
Side-by-side comparison of Occidental Petroleum Corporation (OXY) and Portage Biotech Inc. (PRTG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OXY and PRTG operate in Oil & Gas Production (Energy), so they compete in similar markets.
- OXY is the larger of the two at $59.32B, about 483.2x PRTG ($122.8M).
- OXY has hit the wire 5 times in the past 4 weeks while PRTG has been quiet.
- OXY has more recent analyst coverage (25 ratings vs 5 for PRTG).
Occidental Petroleum Corporation
Occidental Petroleum Corporation, together with its subsidiaries, engages in the acquisition, exploration, and development of oil and gas properties in the United States, the Middle East, Africa, and Latin America. The company operates through three segments: Oil and Gas, Chemical, and Marketing and Midstream. The company's Oil and Gas segment explores for, develops, and produces oil and condensate, natural gas liquids (NGLs), and natural gas. Its Chemical segment manufactures and markets basic chemicals, including chlorine, caustic soda, chlorinated organics, potassium chemicals, ethylene dichloride, chlorinated isocyanurates, sodium silicates, and calcium chloride; vinyls comprising vinyl chloride monomer, polyvinyl chloride, and ethylene. The company's Midstream and Marketing segment gathers, processes, transports, stores, purchases, and markets oil, condensate, NGLs, natural gas, carbon dioxide, and power. This segment also trades around its assets consisting of transportation and storage capacity; and invests in entities. Occidental Petroleum Corporation was founded in 1920 and is headquartered in Houston, Texas.
Portage Biotech Inc.
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Latest OXY
- President and CEO Jackson Richard A. was granted 101,833 shares, increasing direct ownership by 30% to 439,328 units (SEC Form 4)
- Director Hollub Vicki A. was granted 3,183 shares and covered exercise/tax liability with 74,178 shares, decreasing direct ownership by 6% to 1,037,826 units (SEC Form 4) (withholding obligation)
- Occidental Petro upgraded by Barclays with a new price target
- Occidental Petro upgraded by Goldman with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Occidental Petroleum Corporation
- Director Moore Jack B was granted 6,720 shares and covered exercise/tax liability with 1,479 shares, increasing direct ownership by 7% to 76,431 units (SEC Form 4) to cover withholding tax
- Director Bailey Vicky A covered exercise/tax liability with 1,223 shares and was granted 3,734 shares, increasing direct ownership by 19% to 15,490 units (SEC Form 4) (for tax liability)
- Director Robinson Kenneth B. was granted 4,149 shares and covered exercise/tax liability with 913 shares, increasing direct ownership by 27% to 15,359 units (SEC Form 4) to cover taxes
- Director Gould Andrew was granted 4,978 shares and covered exercise/tax liability with 1,494 shares, increasing direct ownership by 8% to 46,334 units (SEC Form 4) (tax withholding)
- Director Gutierrez Carlos M was granted 3,734 shares, increasing direct ownership by 5% to 82,651 units (SEC Form 4)
Latest PRTG
- SEC Form 424B3 filed by Portage Biotech Inc.
- SEC Form 6-K filed by Portage Biotech Inc.
- SEC Form 424B5 filed by Portage Biotech Inc.
- SEC Form 424B3 filed by Portage Biotech Inc.
- SEC Form 6-K filed by Portage Biotech Inc.
- AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem
- SEC Form S-8 filed by Portage Biotech Inc.
- SEC Form 424B3 filed by Portage Biotech Inc.
- SEC Form 424B3 filed by Portage Biotech Inc.
- SEC Form 6-K filed by Portage Biotech Inc.